Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Assets: 2009-2024

Historic Assets for Gyre Therapeutics (GYRE) over the last 15 years, with Dec 2024 value amounting to $125.4 million.

  • Gyre Therapeutics' Assets rose 27.26% to $159.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $159.4 million, marking a year-over-year increase of 27.26%. This contributed to the annual value of $125.4 million for FY2024, which is 7.61% up from last year.
  • Gyre Therapeutics' Assets amounted to $125.4 million in FY2024, which was up 7.61% from $116.5 million recorded in FY2023.
  • Over the past 5 years, Gyre Therapeutics' Assets peaked at $125.4 million during FY2024, and registered a low of $55.7 million during FY2021.
  • Its 3-year average for Assets is $108.9 million, with a median of $116.5 million in 2023.
  • Its Assets has fluctuated over the past 5 years, first crashed by 41.31% in 2021, then skyrocketed by 52.26% in 2022.
  • Gyre Therapeutics' Assets (Yearly) stood at $94.8 million in 2020, then plummeted by 41.31% to $55.7 million in 2021, then soared by 52.26% to $84.8 million in 2022, then soared by 37.50% to $116.5 million in 2023, then increased by 7.61% to $125.4 million in 2024.